NCT02848313View on ClinicalTrials.gov

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2016

Primary Completion Date

March 16, 2018

Study Completion Date

April 10, 2018

Conditions

Age-Related Macular Degeneration

Interventions

DRUG

Elamipretide

40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.

Trial Locations (1)

27710

Duke University School of Medicine / Dept. of Ophthalmology (Duke Eye Center), Durham

All Listed Sponsors

lead

Stealth BioTherapeutics Inc.

INDUSTRY

NCT02848313 - An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter